AU2021231074C1 - Class II, type V CRISPR systems - Google Patents

Class II, type V CRISPR systems Download PDF

Info

Publication number
AU2021231074C1
AU2021231074C1 AU2021231074A AU2021231074A AU2021231074C1 AU 2021231074 C1 AU2021231074 C1 AU 2021231074C1 AU 2021231074 A AU2021231074 A AU 2021231074A AU 2021231074 A AU2021231074 A AU 2021231074A AU 2021231074 C1 AU2021231074 C1 AU 2021231074C1
Authority
AU
Australia
Prior art keywords
sequence
seq
endonuclease
engineered
guide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021231074A
Other languages
English (en)
Other versions
AU2021231074A1 (en
AU2021231074B2 (en
Inventor
Justine ALBERS
Lisa ALEXANDER
Alan Brooks
Christopher Brown
Cristina Butterfield
Cindy CASTELLE
Greg COST
Audra DEVOTO
Daniela S.A. Goltsman
Rebecca LAMOTHE
Morayma TEMOCHE-DIAZ
Brian Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metagenomi Therapeutics Inc
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of AU2021231074A1 publication Critical patent/AU2021231074A1/en
Application granted granted Critical
Publication of AU2021231074B2 publication Critical patent/AU2021231074B2/en
Priority to AU2024200614A priority Critical patent/AU2024200614A1/en
Publication of AU2021231074C1 publication Critical patent/AU2021231074C1/en
Assigned to Metagenomi Therapeutics, Inc. reassignment Metagenomi Therapeutics, Inc. Request to Amend Deed and Register Assignors: METAGENOMI, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Amplifiers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021231074A 2020-03-06 2021-03-06 Class II, type V CRISPR systems Active AU2021231074C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200614A AU2024200614A1 (en) 2020-03-06 2024-02-01 Class II, type V CRISPR systems

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062986477P 2020-03-06 2020-03-06
US62/986,477 2020-03-06
US202063022276P 2020-05-08 2020-05-08
US63/022,276 2020-05-08
US202063045815P 2020-06-29 2020-06-29
US63/045,815 2020-06-29
US202063068316P 2020-08-20 2020-08-20
US63/068,316 2020-08-20
US202063069699P 2020-08-24 2020-08-24
US63/069,699 2020-08-24
US202063116157P 2020-11-19 2020-11-19
US63/116,157 2020-11-19
PCT/US2021/021259 WO2021178933A2 (en) 2020-03-06 2021-03-06 Class ii, type v crispr systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200614A Division AU2024200614A1 (en) 2020-03-06 2024-02-01 Class II, type V CRISPR systems

Publications (3)

Publication Number Publication Date
AU2021231074A1 AU2021231074A1 (en) 2022-09-29
AU2021231074B2 AU2021231074B2 (en) 2023-11-02
AU2021231074C1 true AU2021231074C1 (en) 2024-06-27

Family

ID=77612848

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021231074A Active AU2021231074C1 (en) 2020-03-06 2021-03-06 Class II, type V CRISPR systems
AU2024200614A Pending AU2024200614A1 (en) 2020-03-06 2024-02-01 Class II, type V CRISPR systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200614A Pending AU2024200614A1 (en) 2020-03-06 2024-02-01 Class II, type V CRISPR systems

Country Status (10)

Country Link
US (3) US11713471B2 (https=)
EP (1) EP4114932A4 (https=)
JP (2) JP7605852B2 (https=)
KR (2) KR102647766B1 (https=)
CN (1) CN116096876A (https=)
AU (2) AU2021231074C1 (https=)
CA (1) CA3174557A1 (https=)
GB (2) GB2617658B (https=)
MX (1) MX2022011039A (https=)
WO (1) WO2021178933A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
GB2617658B (en) 2020-03-06 2024-04-17 Metagenomi Inc Class II, type V CRISPR systems
JP2023548588A (ja) * 2020-10-30 2023-11-17 アーバー バイオテクノロジーズ， インコーポレイテッド Ｔｒａｃを標的とするｒｎａガイドを含む組成物及びその使用
US20230072431A1 (en) * 2020-11-03 2023-03-09 Science Solutions Llc Novel class 2 crispr-cas rna-guided endonucleases
US20240376451A1 (en) * 2021-01-07 2024-11-14 Inscripta, Inc. Mad nucleases
KR20240017367A (ko) * 2021-06-02 2024-02-07 메타지노미, 인크. 클래스 ii, v형 crispr 시스템
WO2023056291A1 (en) 2021-09-28 2023-04-06 Acrigen Biosciences Compositions and methods for nucleic acid modifications
CN117050973B (zh) * 2021-10-29 2024-07-19 山东舜丰生物科技有限公司 新型Cas酶和系统以及应用
WO2023092132A1 (en) * 2021-11-22 2023-05-25 Mammoth Biosciences, Inc. Effector proteins and uses thereof
CN116200368A (zh) * 2021-11-30 2023-06-02 上海科技大学 一种基于c2c9核酸酶的新型基因组编辑系统及其应用
AU2023209457A1 (en) * 2022-01-21 2024-08-08 Mammoth Biosciences, Inc. Effector proteins and methods of use
CN119546757A (zh) 2022-05-25 2025-02-28 宏基因组学公司 肝酶表达的补充
US12264328B2 (en) 2022-07-18 2025-04-01 ReNAgade Therapeutics Management, Inc. Gene editing components, systems, and methods of use
JP2025525569A (ja) * 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
WO2024042168A1 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2024107665A1 (en) * 2022-11-14 2024-05-23 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods of use thereof
TW202440913A (zh) * 2022-12-08 2024-10-16 香港商正基基因科技有限公司 Cas12蛋白、CRISPR-Cas系統及其用途
JP2026501682A (ja) * 2023-01-03 2026-01-16 エメンドバイオ・インコーポレイテッド Ｏｍｎｉ ｘｌ１～２２ ｃｒｉｓｐｒヌクレアーゼ
WO2025003358A2 (en) * 2023-06-29 2025-01-02 UCB Biopharma SRL Novel nucleic acid targeting systems comprising rna-guided nucleases
WO2025051140A1 (zh) * 2023-09-04 2025-03-13 中国农业大学 新型CRISPR-Casσ酶和系统
CN118773168B (zh) * 2023-11-24 2025-07-25 华智生物技术有限公司 CRISPR/Cas效应蛋白HT001及系统与应用
EP4574975A1 (en) * 2023-12-20 2025-06-25 Bayer AG Compositions and methods for delivering transgenes
WO2025201316A1 (zh) * 2024-03-25 2025-10-02 深圳华大生命科学研究院 一种CRISPR-Cas系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190264186A1 (en) * 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9963689B2 (en) 2013-12-31 2018-05-08 The Regents Of The University Of California Cas9 crystals and methods of use thereof
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20200263190A1 (en) * 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
US20190161743A1 (en) 2016-05-09 2019-05-30 President And Fellows Of Harvard College Self-Targeting Guide RNAs in CRISPR System
KR102758434B1 (ko) * 2017-03-30 2025-01-21 고쿠리츠 다이가쿠 호진 교토 다이가쿠 게놈 편집에 의한 엑손 스키핑 유도 방법
WO2018195545A2 (en) * 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
CA3102054A1 (en) * 2017-06-05 2018-12-13 Fred Hutchinson Cancer Research Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020536502A (ja) 2017-09-07 2020-12-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子操作のためのヌクレアーゼシステム
US20190247517A1 (en) 2017-10-17 2019-08-15 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing for hemophilia a
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
JP7575271B2 (ja) 2018-03-29 2024-10-29 フェイト セラピューティクス，インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
CA3109083A1 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
US12365888B2 (en) 2018-12-14 2025-07-22 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
EP3931313A2 (en) * 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
AU2020223370B2 (en) 2019-02-14 2023-04-20 Metagenomi Therapeutics, Inc. Enzymes with RuvC domains
CN110684823A (zh) 2019-10-23 2020-01-14 海南大学 一种基于试纸条的Cas12a酶的微生物快速诊断技术
CN110904239B (zh) 2019-12-25 2020-11-10 武汉博杰生物医学科技有限公司 肺癌相关分子标志物基因突变的检测试剂盒与检测方法
WO2021178934A1 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
GB2617658B (en) * 2020-03-06 2024-04-17 Metagenomi Inc Class II, type V CRISPR systems
KR20230021657A (ko) 2020-05-08 2023-02-14 메타지노미, 인크. Ruvc 도메인을 포함하는 효소
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
WO2022159742A1 (en) 2021-01-22 2022-07-28 Metagenomi, Inc Novel engineered and chimeric nucleases
BR112023014719A2 (pt) 2021-01-22 2023-12-05 Metagenomi Inc Novas nucleases quiméricas e manipuladas
EP4281567A4 (en) 2021-01-25 2025-03-05 The Broad Institute Inc. REPROGRAMMABLE TNPB POLYPEPTIDES AND THEIR USE
BR112023018948A2 (pt) 2021-03-19 2023-10-17 Metagenomi Inc Edição multiplex com enzimas cas
KR20240017367A (ko) 2021-06-02 2024-02-07 메타지노미, 인크. 클래스 ii, v형 crispr 시스템
MX2024003007A (es) 2021-09-08 2024-03-25 Metagenomi Inc Sistemas crispr de clase ii, tipo v.
EP4399290A4 (en) 2021-09-08 2025-10-01 Metagenomi Inc CLASS II TYPE V CRISPR SYSTEMS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190264186A1 (en) * 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1

Also Published As

Publication number Publication date
AU2021231074A1 (en) 2022-09-29
US20220290187A1 (en) 2022-09-15
JP2025060673A (ja) 2025-04-10
KR20240036729A (ko) 2024-03-20
JP2023517041A (ja) 2023-04-21
US11713471B2 (en) 2023-08-01
MX2022011039A (es) 2022-12-13
US20230227857A1 (en) 2023-07-20
GB202219438D0 (en) 2023-02-01
EP4114932A2 (en) 2023-01-11
GB2617658B (en) 2024-04-17
GB2603704B (en) 2023-02-15
US12123014B2 (en) 2024-10-22
CA3174557A1 (en) 2021-09-10
EP4114932A4 (en) 2024-03-13
JP7605852B2 (ja) 2024-12-24
GB2603704A (en) 2022-08-10
AU2024200614A1 (en) 2024-04-11
KR102647766B1 (ko) 2024-03-13
GB202205584D0 (en) 2022-06-01
WO2021178933A2 (en) 2021-09-10
KR20220150329A (ko) 2022-11-10
WO2021178933A3 (en) 2021-12-23
US20240093239A1 (en) 2024-03-21
CN116096876A (zh) 2023-05-09
AU2021231074B2 (en) 2023-11-02
GB2617658A (en) 2023-10-18

Similar Documents

Publication Publication Date Title
AU2021231074C1 (en) Class II, type V CRISPR systems
US20240117330A1 (en) Enzymes with ruvc domains
US12024727B2 (en) Enzymes with RuvC domains
US20230416710A1 (en) Engineered and chimeric nucleases
KR20240055073A (ko) 클래스 ii, v형 crispr 시스템
US20240218339A1 (en) Class ii, type v crispr systems
CN113728097A (zh) 具有ruvc结构域的酶
US20220220460A1 (en) Enzymes with ruvc domains
KR20240049306A (ko) Ruvc 도메인을 갖는 효소
EP4200422A1 (en) Systems and methods for transposing cargo nucleotide sequences
US20250002881A1 (en) Class ii, type v crispr systems
US20250059568A1 (en) Class ii, type v crispr systems
CN117693585A (zh) Ii类v型crispr系统
GB2617659A (en) Enzymes with RUVC domains

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 DEC 2023

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 MAR 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 19 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 18 MAR 2024

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: METAGENOMI THERAPEUTICS, INC.

Free format text: FORMER NAME(S): METAGENOMI, INC.